Payment overview · 2025
General Payments
$682.87
37 reported records · 10 companies
Healthcare provider profile · identity verified
Lionel Ramirez, MD
Allopathic & Osteopathic Physicians|General Practice · KISSIMMEE, FL · NPI 1508387200
Verified facts
What the public records show
CMS Open Payments records show Lionel Ramirez, MD received $682.87 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.91 | 26.4% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.77 | 13.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.97 | 11.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.60 | 11.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.08 | 10.6% | 4 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $56.08 | 8.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.34 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.31 | 5.0% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $31.67 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.14 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $682.87 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.13 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.77 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.97 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.60 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.70 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $72.08 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.78 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 232 |
| Losartan Potassium | Losartan Potassium | 462 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 126 |
| Lisinopril | Lisinopril | 358 | 127 |
| Metformin Hcl | Metformin Hcl | 356 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 126 |
| Gabapentin | Gabapentin | 299 | 119 |
| Simvastatin | Simvastatin | 235 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 60 |
| Meloxicam | Meloxicam | 198 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 73 |
| Omeprazole | Omeprazole | 189 | 81 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 77 |
| Famotidine | Famotidine | 171 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 64 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 69 |
| Trazodone Hcl | Trazodone Hcl | 141 | 49 |
| Carvedilol | Carvedilol | 140 | 49 |
| Furosemide | Furosemide | 140 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 48 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 128 | 44 |
| Montelukast Sodium | Montelukast Sodium | 126 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 36 |
| Ezetimibe | Ezetimibe | 111 | 39 |
| Azithromycin | Azithromycin | 110 | 86 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 36 |
| Alendronate Sodium | Alendronate Sodium | 102 | 35 |
| Prednisone | Prednisone | 100 | 70 |
| Buspirone Hcl | Buspirone Hcl | 97 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 41 |
| Glimepiride | Glimepiride | 89 | 32 |
| Jardiance | Empagliflozin | 89 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 79 | 28 |
| Alprazolam | Alprazolam | 78 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 25 |
| Tramadol Hcl | Tramadol Hcl | 77 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 28 |
| Farxiga | Dapagliflozin Propanediol | 75 | 27 |
| Ibandronate Sodium | Ibandronate Sodium | 74 | 30 |
| Metformin Hcl Er | Metformin Hcl | 73 | 31 |
| Eliquis | Apixaban | 72 | 28 |
| Levofloxacin | Levofloxacin | 71 | 63 |
| Allopurinol | Allopurinol | 70 | 20 |
| Ibuprofen | Ibuprofen | 69 | 21 |
| Clonidine Hcl | Clonidine Hcl | 66 | 23 |
| Azelastine Hcl | Azelastine Hcl | 63 | 31 |
| Glipizide | Glipizide | 63 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 26 |
| Sertraline Hcl | Sertraline Hcl | 60 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 57 | 15 |
| Baclofen | Baclofen | 53 | 27 |
| Atenolol | Atenolol | 52 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 19 |
| Celecoxib | Celecoxib | 50 | 20 |
| Sucralfate | Sucralfate | 50 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 21 |
| Finasteride | Finasteride | 47 | 19 |
| Lovastatin | Lovastatin | 47 | 21 |
| Ozempic | Semaglutide | 47 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 42 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 30 |
| Clonazepam | Clonazepam | 44 | 15 |
| Potassium Chloride | Potassium Chloride | 44 | 18 |
| Ciclopirox | Ciclopirox | 43 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Benazepril Hcl | Benazepril Hcl | 39 | 14 |
| Donepezil Hcl | Donepezil Hcl | 39 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Telmisartan | Telmisartan | 38 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 21 |
| Meclizine Hcl | Meclizine Hcl | 37 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | 16 |
| Temazepam | Temazepam | 36 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Folic Acid | Folic Acid | 35 | 12 |
| Glipizide Er | Glipizide | 35 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Spironolactone | Spironolactone | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 14 |
| Methocarbamol | Methocarbamol | 31 | 17 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Valsartan | Valsartan | 30 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 12 |
| Lactulose | Lactulose | 29 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 11 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | 11 |
| Mupirocin | Mupirocin | 25 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | 13 |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | 12 |
| Naproxen | Naproxen | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | 11 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Topiramate | Topiramate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Tadalafil | Tadalafil | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | 11 |
| Latanoprost | Latanoprost | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 16 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 13 |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Glipizide Xl | Glipizide | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $682.87 · 37 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, RELISTOR, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error